OpenEvidence Raises $200M: The ChatGPT for Doctors

OpenEvidence Secures $200 Million Funding

OpenEvidence, a platform described by healthcare professionals as a medical equivalent to ChatGPT, is poised to reveal a new funding round of $200 million.

This investment values the company at $6 billion, according to reports from The New York Times.

Rapid Growth and Investor Confidence

The new capital arrives just three months following a $210 million raise, which established a $3.5 billion valuation.

This demonstrates significant investor enthusiasm for specialized AI applications within specific industries.

Leveraging Medical Literature for Enhanced Patient Care

The OpenEvidence platform is trained using authoritative medical publications, including journals like JAMA and the New England Journal of Medicine.

It facilitates rapid access to established medical knowledge, assisting healthcare providers in patient treatment decisions.

Access to the tool is provided at no cost to verified medical professionals, with the platform’s operation supported through advertising revenue.

Impressive User Growth

Since its inception in 2022, OpenEvidence has experienced substantial growth.

The number of clinical consultations conducted monthly through the platform has nearly doubled, reaching 15 million as of July, as reported by the Times.

Investment Details

Google Ventures spearheaded the funding round.

Notable participants included Sequoia Capital, Kleiner Perkins, Blackstone, Thrive Capital, Coatue Management, Bond, and Craft.

TechCrunch has contacted OpenEvidence seeking further commentary.